◀ Back to MTOR

MTOR — PDK1

Text-mined interactions from Literome

Mason et al., IDrugs 2010 (Neoplasms) : This conference report highlights selected presentations on preclinical data on the novel pan-PI3K pyrimidine derived inhibitor BKM-120 ( Novartis AG ), the dual inhibition of mTOR/PI3K in NSCLC by PF-4691502 ( Pfizer Inc ), the small-molecule PDK-1 inhibitors PF-05177624 and PF-05197281 ( both Pfizer ) and the ability of RO-5323441 ( F Hoffmann-La Roche Ltd/ThromboGenics NV/BioInvent International AB ) to block tumor growth in vivo
Finlay et al., J Exp Med 2012 : PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells